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Abstract
Triage tools have an important role in pandemics to identify those most likely to benefit from higher levels of care. We
compared Community Assessment Tools (CATs), the CURB-65 score, and the Pandemic Medical Early Warning Score
(PMEWS); to predict higher levels of care (high dependency - Level 2 or intensive care - Level 3) and/or death in patients at
or shortly after admission to hospital with A/H1N1 2009 pandemic influenza. This was a case-control analysis using
retrospectively collected data from the FLU-CIN cohort (1040 adults, 480 children) with PCR-confirmed A/H1N1 2009
influenza. Area under receiver operator curves (AUROC), sensitivity, specificity, positive predictive values and negative
predictive values were calculated. CATs best predicted Level 2/3 admissions in both adults [AUROC (95% CI): CATs 0.77 (0.73,
0.80); CURB-65 0.68 (0.64, 0.72); PMEWS 0.68 (0.64, 0.73), p,0.001] and children [AUROC: CATs 0.74 (0.68, 0.80); CURB-65 0.52
(0.46, 0.59); PMEWS 0.69 (0.62, 0.75), p,0.001]. CURB-65 and CATs were similar in predicting death in adults with both
performing better than PMEWS; and CATs best predicted death in children. CATs were the best predictor of Level 2/3 care
and/or death for both adults and children. CATs are potentially useful triage tools for predicting need for higher levels of
care and/or mortality in patients of all ages.
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Introduction
Triage tools identifying need for higher levels of care and risk of
severe outcome have an important role in pandemic situations
where secondary care capacity may be insufficient to meet demand
[1]. The time available for clinical decision making may be limited
by workload pressures and healthcare workers unfamiliar with
clinical assessment and admission decision making may be asked to
fulfil ‘gatekeeper’ roles. The CURB-65 score is a validated predictor
of 30-day mortality from community acquired pneumonia in adults
but was never intended for use in children [2,3]. The CURB-65
score does not performas well in predicting higherlevels of care and
was not designed to predict mortality from non-pneumonic
presentations [4,5]. Challen et al proposed the Pandemic Medical
Early Warning Score (PMEWS) as a clinical triage tool to aid
hospital admission decisions for adults in a pandemic situation [6].
They validated PMEWS in adults presenting to hospital with
community acquired pneumonia and found that it was better than
the CURB-65 score for predicting need for admission and higher
levels of care but had limited ability to predict mortality.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34428In 2009, the Department of Health England published a
package of care that included Community Assessment Tools
(CATs) and patient pathways for use by the NHS in a severe
pandemic event [7]. CATs were developed to help non-specialist
front-line staff identify which sick children and adults are most
likely to benefit from interventions and levels of care only available
in hospitals when resources are limited. CATs use six objective and
one subjective criteria based on simple clinical assessment.
Meeting any CATs criterion warrants referral and admission to
hospital. Criteria are:
A) Severe respiratory distress,
B) Increased respiratory rate,
C) Oxygen saturation #92% on pulse oximetry breathing air,
or on oxygen,
D) Respiratory exhaustion,
E) Severe dehydration or shock,
F) Altered consciousness level and
G) Causing other clinical concern.
While criterion fields are common to adult and paediatric
CATs, the abnormal physiological thresholds and clinical signs are
age-appropriate. Like PMEWS, there is no requirement for
laboratory investigation to complete the assessment. CATs were
only intended for use ‘‘during severe and exceptional circum-
stances when surge demand for healthcare services leads to a need
for strict triage’’; and as such, were not deployed during the 2009/
10 pandemic.
Goodacre and colleagues (2010) conducted an evaluation of the
discriminatory value of the CURB-65 score, PMEWS and CATs
for predicting severe illness or mortality in patients with suspected
pandemic influenza, but were unable to draw any conclusions
regarding their clinical utility in a pandemic situation due to
insufficient case numbers especially of adults, and a low incidence
of severe outcome [8]. We aimed to use data from the much larger
Influenza Clinical Information Network (FLU-CIN) cohort to
compare the clinical validity and utility of CATs, CURB-65 and
PMEWS as predictors for higher levels of care, in-patient mortality
and severe combined outcome in pandemic influenza.
Methods
FLU-CIN was an ‘emergency’ surveillance network established
by the Department of Health England. FLU-CIN used a
purposive sampling frame based on 13 sentinel hospitals situated
in five clinical ‘hubs’ in Nottingham, Leicester, London, Sheffield
and Liverpool, with contributions from a further 45 non-sentinel
hospitals in England and 17 in Scotland, Wales and Northern
Ireland. Between April 2009 and January 2010, clinical,
epidemiological and outcome data were collected on 1520 patients
(800 female, 480 children ,16 years) admitted to participating
UK hospitals with confirmed A/H1N1 2009 influenza infection.
The details of data collection and the findings have been
described elsewhere [9]. A/H1N1 2009 influenza infection was
diagnosed by a positive reverse transcribed polymerase chain
reaction (PCR) result from respiratory samples obtained during
the admission episode. Data was gathered from routine case notes
using the first recorded routine clinical assessment on or shortly
after admission. A case-controlled analysis using retrospective data
of the predictive ability of CATs, CURB-65 and PMEWS was
conducted using the full FLU-CIN cohort. Analyses were
conducted by age group. A complete case analysis was used.
CATs scores were calculated by awarding a single point for each
of the following: severe respiratory distress, increased respiratory
rate, oxygen saturation #92% (in air or supplemental oxygen),
respiratory exhaustion, severe clinical dehydration, altered con-
sciousness and a maximum of one point for causing any other
clinical concern to the attending clinicians; on or shortly after
admission to hospital. The definitions for CATs criteria differ for
children and adults and are provided in Appendix S1. CURB-65
scores were calculated by awarding one point for each of the
following: confusion, urea .7 mmol/l, respiratory rate $30/
minute, low systolic (,90 mmHg) or diastolic (#60 mmHg) blood
pressure and age $65 years [2]. PMEWS scores were calculated
using the algorithm described by Challen et al. with points being
allocated on a weighted basis for varying values of the following
indicators: respiratory rate, oxygen saturation, heart rate, systolic
blood pressure, temperature, neurological signs (level of alertness).
In addition, a point was awarded for age $65 years, social
isolation, chronic disease and performance status of limited activity
(modified Karnofsky .2) [6].
The discriminatory value of the three tools was initially
compared using logistic regression to assess whether various
outcomes: patients admitted to higher levels of care (high
dependency care - Level 2 or intensive care - Level 3), death, or
severe outcomes as a whole (a combined measure indicating either
Level 2/3 admission or death); were more likely to have higher
scores than controls. Each scoring system was included in a
univariable logistic model as a continuous variable on the
assumption that the scores would follow a linear trend.
Results were presented as unadjusted Odds Ratios (ORs) and 95
per cent Confidence Intervals (95% CI). The resulting ORs could
therefore be interpreted as the increased likelihood of a given
clinical outcome for every unit increase on the scoring scale.
The three tools were then compared on their ability to predict:
admission to higher levels of care, death or severe outcome
(combined higher level of care and or death); using area under the
Receiver Operating Characteristic (ROC) curve (AUROC)
comparisons with 95% confidence intervals. Calibration of the
model was tested using the Hosmer-Lemeshow goodness-of-fit test.
The sensitivity (the proportion of true positives that are correctly
identified by the test), specificity (the proportion of true negatives
that were correctly predicted by the test), positive predictive value
(PPV) i.e., the proportion of test positive patients who actually had
the outcome; and negative predictive value (NPV) i.e., the
proportion of test negative patients who were actually negative
for the outcome, were calculated for each of the tools using various
score thresholds. All analyses were carried out using Stata version
11.0 (StataCorp. 2009).
Before commencement, FLU-CIN procedures were reviewed by
the Ethics and Confidentiality Committee of the National
Information Governance Board for Health and Social Care in
England and approved for collection, storage and use of personal
data for surveillance purposes.
Results
The study sample comprised 1040 (68.4%) adults and 480
(31.6%) children (age,16 years) admitted to hospital in two
pandemic waves: Spring/Summer 2009 (n=601) and Autumn/
Winter 2009/10 (n=919). The median age was 26 years
(interquartile range 9 to 44 years). There were 800 (52.6%)
females of whom 83 aged 14 to 44 years were pregnant (20.8%).
The clinical characteristics of the first-wave cohort have been
described previously [9]. Tables 1 and 2 present the distribution of
CATs scores, CURB-65 scores and PMEWS scores by admission
to higher levels of care and mortality. Results are presented as
unadjusted Odds Ratios (ORs) and 95% Confidence Intervals
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increased likelihood of a given clinical outcome for every unit
increase on each scoring scale. For each of the triage tools, adult
patients with any severe outcome (higher level of care and/or in-
patient death) were more likely to have higher scores as compared
to controls. In children, both CATs and PMEWS scores were
more likely to be higher in patients with severe outcomes.
Calibration i.e. the proximity of observed and expected values
or goodness-of-fit of the logistic regression models was tested using
the Hosmer-Lemeshow goodness-of-fit test. In adults, the
outcomes ‘Level 2 or 3 admission’ and ‘Death’, all logistic
regression models for all three triage tools (CATs, CURB-65 and
PMEWS) showed good calibration. When considering combined
severe outcomes (Level 2/3 admission or death), only CATs and
CURB-65 demonstrated good calibration between observed and
expected values; PMEWS had a poor fit (p=0.0453). In children,
CATs was the only triage tool for which the logistic regression
model showed good calibration for all three outcomes. Both
CURB-65 and PMEWS showed good calibration between
observed and expected values for ‘death’ but poor calibration
when used for predicting ‘Level 2 or 3 admission’ (p=0.0204 and
p=0.0176 respectively).
The ROC curves and AUROC values comparing the predictive
value of the three clinical triage tools are described in figure 1.
CATs showed the best predictive performance for Level 2/3
admissions in both adults [AUROC (95% CI): CATs 0.77 (0.73,
0.80); CURB-65 0.68 (0.64, 0.72); PMEWS 0.68 (0.64, 0.73),
comparison of AUROCs p,0.001, n=1040] and children
[AUROC (95% CI): CATs 0.74 (0.68, 0.80); CURB-65 0.52
(0.46, 0.59); PMEWS 0.69 (0.62, 0.75), p,0.001, n=480].
Table 1. Distribution of CATs, CURB-65 and PMEWS scores according to outcome measures (Level 2/3 admission, mortality,
combined measure of severe outcomes) in adults ($16 years).
Triage tool Level 2 or 3 admission Death Combined severe outcomes*
Yes (n=177) No (n=863) Yes (n=62) No (n=978) Yes (n=191) No (n=849)
CATs scores
0 10 (5.7%) 224 (26.0%) 6 (9.7%) 228 (23.3%) 12 (6.3%) 222 (26.2%)
1 27 (15.3%) 306 (35.5%) 10 (16.1%) 323 (33.0%) 30 (15.7%) 303 (35.7%)
2 54 (30.5%) 223 (25.8%) 17 (27.4%) 260 (26.6%) 57 (26.7%) 220 (25.9%)
3 47 (26.6%) 96 (11.1%) 17 (27.4%) 126 (12.9%) 51 (26.7%) 92 (10.8%)
4 31 (17.5%) 14 (1.6%) 10 (16.1%) 35 (3.6%) 33 (17.3%) 12 (1.4%)
5 5 (2.8%) 0 (0.0%) 1 (1.6%) 4 (0.4%) 5 (2.6%) 0 (0.0%)
6 1 (0.6%) 0 (0.0%) 0 (0.0%) 1 (0.1%) 1 (0.5%) 0 (0.0%)
7 2 (1.1%) 0 (0.0%) 1 (1.6%) 1 (0.1%) 2 (1.1%) 0 (0.0%)
Unadjusted OR (95% CI) 4.61 (3.45, 6.16); p trend,0.001 2.83 (1.91, 4.19); p trend,0.001 4.57 (3.44, 6.07); p trend,0.001
CURB-65 scores
0 32 (18.1%) 380 (44.0%) 6 (9.7%) 406 (41.5%) 33 (17.3%) 379 (44.6%)
1 70 (39.6%) 321 (37.2%) 26 (41.9%) 365 (37.3%) 75 (39.3%) 316 (37.2%)
2 50 (28.3%) 138 (16.0%) 22 (35.5%) 166 (17.0%) 56 (29.3%) 132 (15.6%)
3 24 (13.6%) 24 (2.8%) 8 (12.9%) 40 (4.1%) 26 (13.6%) 22 (2.6%)
4 1 (0.6%) 0 (0.0%) 0 (0.0%) 1 (0.1%) 1 (0.5%) 0 (0.0%)
Unadjusted OR (95% CI) 2.15 (1.79, 2.59); p trend,0.001 2.20 (1.68, 2.90); p trend,0.001 2.26 (1.89, 2.72); p trend,0.001
PMEWS scores
0 0 (0.0%) 1 (0.1%) 0 (0.0%) 1 (0.1%) 0 (0.0%) 1 (0.1%)
1 4 (2.3%) 53 (6.1%) 1 (1.6%) 56 (5.7%) 4 (2.1%) 53 (6.2%)
2 13 (7.3%) 96 (11.1%) 7 (11.3%) 102 (10.4%) 16 (8.4%) 93 (11.0%)
3 10 (5.7%) 131 (15.2%) 6 (9.7%) 135 (13.8%) 12 (6.3%) 129 (15.2%)
4 15 (8.5%) 125 (14.5%) 7 (11.3%) 133 (13.6%) 16 (8.4%) 124 (14.6%)
5 12 (6.8%) 130 (15.1%) 2 (3.2%) 140 (14.3%) 13 (6.8%) 129 (15.2%)
6 25 (14.1%) 110 (12.8%) 10 (16.1%) 125 (12.8%) 28 (14.7%) 107 (12.6%)
7 31 (17.5%) 79 (9.2%) 12 (19.4%) 98 (10.0%) 33 (17.3%) 77 (9.1%)
8 23 (13.0%) 49 (5.7%) 4 (6.5%) 68 (7.0%) 24 (12.6%) 48 (5.7%)
9 20 (11.3%) 58 (6.7%) 7 (11.3%) 71 (7.3%) 20 (10.5%) 58 (6.8%)
10 15 (8.5%) 20 (2.3%) 4 (6.5%) 31 (3.2%) 15 (7.9%) 20 (2.4%)
11 5 (2.8%) 8 (0.9%) 1 (1.6%) 12 (1.2%) 6 (3.1%) 7 (0.8%)
$12 4 (2.3%) 3 (0.4%) 1 (1.6%) 6 (0.6%) 4 (2.1%) 3 (0.4%)
Unadjusted OR (95% CI) 1.29 (1.21, 1.38); p trend,0.001 1.14 (1.03, 1.26); p trend=0.009 1.27 (1.19, 1.36); p trend,0.001
*Combined measure of severe outcomes (Level 2/3 admission or death).
doi:10.1371/journal.pone.0034428.t001
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patient mortality in adults [AUROC (95% CI): CATs 0.70 (0.63,
0.77); CURB-65 0.71 (0.65, 0.77); PMEWS 0.60 (0.52, 0.67),
p=0.009] but CATs performed best as a predictor of mortality in
children [AUROC (95% CI): CATs 0.76 (0.66, 0.86); CURB-65
0.51 (0.39, 0.63); PMEWS 0.69 (0.55, 0.83), p=0.002].
CATs were the best predictor of severe outcome defined as a
combined measure of either Level 2/3 admission or in-patient
death; for both adults [AUROC (95% CI): CATs 0.76 (0.73, 0.80);
CURB-65 0.69 (0.65, 0.72); PMEWS 0.67 (0.63, 0.71), p,0.001]
and children [AUROC (95% CI): CATs 0.76 (0.70, 0.82); CURB-
65 0.53 (0.46, 0.59); PMEWS 0.69 (0.63, 0.76), p,0.001].
In a sensitivity analysis restricted to adults with A/H1N1 2009
and a diagnosis of pneumonia validated by radiographic reports;
the adult CATs was the best predictor of Level 2/3 admission
[AUROC (95% CI): CATs 0.78 (0.72, 0.83); CURB-65 0.70 (0.63,
0.77); PMEWS 0.70 (0.6, 0.76), p=0.034]. CURB-65 and adult
CATs were similar and better than PMEWS in predicting in-
patient death [AUROC (95% CI): CURB-65 0.73 (0.63, 0.82);
CATs 0.66 (0.56, 0.76); PMEWS 0.58 (0.46, 0.69), p=0.038]. The
adult CATs was the best predictor of severe outcome [AUROC
(95% CI): CATs 0.77 (0.71, 0.83); CURB-65 0.71 (0.65, 0.78);
PMEWS 0.68 (0.61, 0.74), p=0.027].
Tables 3 and 4 explore the clinical utility of various threshold
scores for each of the triage tools. In adults, a CATs score $3 was
the best predictor of Level 2/3 admissions or in-patient death or
combined severe outcome when compared to various cut-off
scores for either CURB-65 or PMEWS. In children, a CATs score
$3 was the best predictor of Level 2/3 admission and combined
severe outcome; performing marginally better than a PMEWS
Table 2. Distribution of CATs, CURB-65 and PMEWS scores according to outcome measures (Level 2/3 admission, mortality,
combined measure of severe outcomes) in children (,16 years).
Triage tool Level 2 or 3 admission Death Combined severe outcomes*
Yes (n=73) No (n=407) Yes (n=18) No (n=462) Yes (n=77) No (n=403)
CATs scores
0 1 (9.6%) 148 (36.4%) 1 (5.6%) 154 (33.3%) 7 (9.1%) 148 (36.7%)
1 18 (24.7%) 151 (37.1%) 3 (16.7%) 166 (35.9%) 18 (23.4%) 151 (37.5%)
2 22 (30.1%) 72 (17.7%) 8 (44.4%) 86 (18.6%) 23 (29.9%) 71 (17.6%)
3 19 (26.0%) 33 (8.1%) 4 (22.2%) 48 (10.4%) 21 (27.3%) 31 (7.7%)
4 5 (6.9%) 2 (0.5%) 1 (5.6%) 6 (1.3%) 5 (6.5%) 2 (0.5%)
5 2 (2.7%) 1 (0.3%) 1 (5.6%) 2 (0.4%) 3 (3.9%) 0 (0.0%)
6 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
7 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Unadjusted OR (95% CI) 3.76 (2.47, 5.71); p trend,0.001 3.18 (1.60, 6.31); p trend=0.001 4.39 (2.86, 6.72); p trend,0.001
CURB-65 scores
0 5 (6.9%) 62 (15.2%) 1 (5.6%) 66 (14.3%) 5 (6.5%) 62 (15.4%)
1 38 (52.1%) 169 (41.5%) 10 (55.6%) 197 (42.6%) 40 (52.0%) 167 (41.4%)
2 25 (34.3%) 166 (40.8%) 6 (33.3%) 185 (40.0%) 27 (35.1%) 164 (40.7%)
3 5 (6.9%) 10 (2.5%) 1 (5.6%) 14 (3.0%) 5 (6.5%) 10 (2.5%)
4 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Unadjusted OR (95% CI) 1.21 (0.86, 1.70); p trend=0.264 1.14 (0.60, 2.14); p trend=0.694 1.23 (0.88, 1.71); p=0.226
PMEWS scores
0 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
1 0 (0.0%) 8 (2.0%) 0 (0.0%) 8 (1.7%) 0 (0.0%) 8 (2.0%)
2 0 (0.0%) 16 (3.9%) 0 (0.0%) 16 (3.5%) 0 (0.0%) 16 (4.0%)
3 1 (1.4%) 14 (3.4%) 0 (0.0%) 15 (3.3%) 1 (1.3%) 14 (3.5%)
4 3 (4.1%) 24 (5.9%) 1 (5.6%) 26 (5.6%) 3 (3.9%) 24 (6.0%)
5 2 (2.7%) 31 (7.6%) 1 (5.6%) 32 (6.9%) 2 (2.6%) 31 (7.7%)
6 4 (5.5%) 51 (12.5%) 0 (0.0%) 55 (11.9%) 4 (5.2%) 51 (12.7%)
7 12 (16.4%) 67 (16.5%) 4 (22.2%) 75 (16.2%) 13 (16.9%) 66 (16.4%)
8 11 (15.1%) 70 (17.2%) 1 (5.6%) 80 (17.3%) 11 (14.3%) 70 (17.4%)
9 17 (23.3%) 93 (22.9%) 4 (22.2%) 106 (22.9%) 19 (24.7%) 91 (22.6%)
10 5 (6.9%) 24 (5.9%) 2 (11.1%) 27 (5.8%) 6 (7.8%) 23 (5.7%)
11 8 (11.0%) 6 (1.5%) 1 (5.6%) 13 (2.8%) 8 (10.4%) 6 (1.5%)
$12 10 (13.7%) 3 (0.7%) 4 (22.2%) 9 (2.0%) 10 (13.0%) 3 (0.7%)
Unadjusted OR (95% CI) 1.47 (1.27, 1.69); p trend,0.001 1.48 (1.15, 1.91); p trend=0.003 1.48 (1.29, 1.70); p trend,0.001
*Combined measure of severe outcomes (Level 2/3 admission or death).
doi:10.1371/journal.pone.0034428.t002
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PMEWS score .9 was the best predictor of mortality in children;
performing marginally better than a CATs score .3, both
significantly better than CURB-65.
Discussion
There has been only one head-to-head validation of the
performance of CURB-65, PMEWS and CATs during the 2009
pandemic period [8]. Our study has the advantages of large size
(n=1520), confirmation of cases by standardised PCR criteria,
and relatively few missing data. Reported cases were followed up
without selection and the acquisition of cases closely mirrored the
national epidemic curve geographically and temporally [10].
Overall, 16.5% of patients required high dependency or intensive
care and 5.3% died.
Two characteristics are crucial when evaluating a clinical
prediction test or algorithm: clinical validity and clinical utility.
Simon defines clinical validity as the ability of the test result to
correlate with a clinical end point or characteristic [11]. Our
results show that for each of the three clinical triage tools, a higher
score is associated with a greater likelihood of severe clinical
outcomes in adult cases, indicating that all three demonstrate
clinical validity. In the case of children however, only CATs and
PMEWS demonstrate this linear relationship. The ROC curves
and AUROC analysis show that in terms of overall performance,
CATs are significantly better than CURB-65 or PMEWS as a
predictor of combined severe outcomes across all age groups.
Figure 1. The predictive values of CATs, CURB-65 and PMEWS for predicting severe outcomes in adults and children with pandemic
influenza. ROC curves comparing the predictive value of CATs (black solid line), CURB-65 (grey dash line) and PMEWS (black dash line) in relation to
Level 2/3 admissions (upper panels), mortality (middle panels) and combined severe outcomes (lower panels) in adults (left panels, age $16 years,
n=1040) and children (right panels, age,16 years, n=480).
doi:10.1371/journal.pone.0034428.g001
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mortality in adults but CATs has better performance in predicting
admission to higher levels of care. It can be argued that the latter
outcome is more meaningful for clinicians as the primary aim of
triage tools is to identify patients who are most likely to benefit
from higher levels of care rather than those most likely to die.
The CURB-65 score is validated only for use in adults with
community acquired pneumonia to predict 30-day mortality
[12,13]. CURB-65 was not developed for use in non-pneumonic
respiratory tract infections nor to predict need for intensive care
admission. Results from the current study reinforce these points.
A predictive test has clinical utility only if the use of the test
results in improved outcomes for patients [11]. Although clinical
utility can only be fully evaluated in a separate prospective cohort,
the first step towards this is to determine a suitable threshold value
that can discriminate between alternative clinical outcomes.
Ideally, a good prediction test should have both high sensitivity
and specificity. There is usually a trade-off between sensitivity and
Table 3. Predictive values of CATs, CURB-65 and PMEWS scores for predicting severe outcomes in adults ($16 years, n=1040).
Outcome Score ROC area (95%CI) Sensitivity % (95%CI) Specificity % (95%CI) PPV % (95%CI) NPV % (95%CI)
Level 2/3 admission CURB-65$2 0.62 (0.58, 0.66) 42.4 (35.0, 50.0) 81.2 (78.5, 83.8) 31.6 (25.8, 38.0) 87.3 (84.8, 89.5)
CURB-65$3 0.56 (0.53, 0.58) 14.1 (9.4, 20.1) 97.2 (95.9, 98.2) 51.0 (36.3, 65.6) 84.7 (82.3, 86.9)
PMEWS.1 0.52 (0.51, 0.53) 97.7 (94.3, 99.4) 6.3 (4.7, 8.1) 17.6 (15.3, 20.1) 93.1 (83.3, 98.1)
PMEWS.2 0.54 (0.51, 0.56) 90.4 (85.1, 94.3) 17.4 (14.9, 20.1) 18.3 (15.8, 21.1) 89.8 (84.2, 94.0)
PMEWS.3 0.54 (0.51, 0.56) 90.4 (85.1, 94.3) 17.4 (14.9, 20.1) 18.3 (15.8, 21.1) 89.8 (84.2, 94.0)
PMEWS.4 0.59 (0.56, 0.62) 84.7 (78.6, 89.7) 32.6 (29.4, 35.8) 20.5 (17.6, 23.6) 91.2 (87.5, 94.1)
PMEWS.5 0.62 (0.58, 0.65) 76.3 (69.3, 82.3) 47.0 (43.7, 50.4) 22.8 (19.5, 26.4) 90.6 (87.5, 93.2)
PMEWS.7 0.65 (0.61, 0.69) 55.4 (47.7, 62.8) 74.9 (71.8, 77.7) 31.1 (26.0, 36.5) 89.1 (86.6, 91.3)
PMEWS.9 0.57 (0.54, 0.61) 24.9 (18.7, 31.9) 89.7 (87.5, 91.6) 33.1 (25.2, 41.8) 85.3 (82.9, 87.6)
PMEWS.11 0.52 (0.50, 0.54) 5.1 (2.4, 9.4) 98.7 (97.7, 99.4) 45.0 (23.1, 68.5) 83.5 (81.1, 85.8)
CATs$3 0.68 (0.64, 0.72) 48.6 (41.0, 56.2) 87.3 (84.8, 89.4) 43.9 (36.8, 51.1) 89.2 (86.9, 91.2)
CATs$4 0.60 (0.57, 0.63) 22.0 (16.2, 28.9) 98.4 (97.3, 99.1) 73.6 (59.7, 84.7) 86.0 (83.7, 88.1)
CATs$5 0.52 (0.51, 0.54) 4.5 (2.0, 8.7) 100.0 (99.6, 100.0) 100.0 (63.1, 100.0) 83.6 (81.2, 85.8)
Death CURB-65$2 0.64 (0.57, 0.70) 48.4 (35.5, 61.4) 78.8 (76.1, 81.4) 12.7 (8.7, 17.6) 96.0 (94.4, 97.3)
CURB-65$3 0.54 (0.50, 0.59) 12.9 (5.7, 23.9) 95.8 (94.4, 97.0) 16.3 (7.3, 29.7) 94.6 (92.9, 95.9)
PMEWS.1 0.52 (0.50, 0.54) 98.4 (91.3, 100.0) 5.8 (4.4, 7.5) 6.2 (4.8, 7.9) 98.3 (90.8, 100.0)
PMEWS.2 0.52 (0.47, 0.56) 87.1 (76.1, 94.3) 16.3 (14.0, 18.7) 6.2 (4.7, 8.0) 95.2 (90.8, 97.9)
PMEWS.3 0.52 (0.47, 0.56) 87.1 (76.1, 94.3) 16.3 (14.0, 18.7) 6.2 (4.7, 8.0) 95.2 (90.8, 97.9)
PMEWS.4 0.54 (0.48, 0.59) 77.4 (65.0, 87.1) 30.1 (27.2, 33.0) 6.6 (4.9, 8.6) 95.5 (92.5, 97.5)
PMEWS.5 0.55 (0.49, 0.61) 66.1 (53.0, 77.7) 43.7 (40.5, 46.8) 6.9 (5.0, 9.3) 95.3 (92.9, 97.1)
PMEWS.7 0.59 (0.52, 0.65) 46.8 (34.0, 59.9) 70.8 (67.8, 73.6) 9.2 (6.3, 13.0) 95.4 (93.7, 96.8)
PMEWS.9 0.54 (0.49, 0.60) 21.0 (11.7, 33.2) 87.7 (85.5, 89.7) 9.8 (5.3, 16.1) 94.6 (92.9, 96.0)
PMEWS.11 0.51 (0.48, 0.53) 3.2 (0.4, 11.2) 98.2 (97.1, 98.9) 10.0 (1.2, 31.7) 94.1 (92.5, 95.5)
CATs$3 0.65 (0.58, 0.71) 46.8 (34.0, 59.9) 82.9 (80.4, 85.2) 14.8 (10.1, 20.6) 96.1 (94.6, 97.3)
CATs$4 0.58 (0.53, 0.63) 19.4 (10.4, 31.4) 95.8 (94.4, 97.0) 22.6 (12.3, 36.2) 94.9 (93.4, 96.2)
CATs$5 0.51 (0.49, 0.54) 3.2 (0.4, 11.2) 99.4 (98.7, 99.8) 25.0 (3.2, 65.1) 94.2 (92.6, 95.5)
Combined severe* CURB-65$2 0.63 (0.59, 0.66) 43.5 (36.3, 50.8) 81.9 (79.1, 84.4) 35.0 (29.0, 41.5) 86.6 (84.0, 88.8)
CURB-65$3 0.56 (0.53, 0.58) 14.1 (9.5, 19.9) 97.4 (96.1, 98.4) 55.1 (40.2, 69.3) 83.5 (81.0, 85.7)
PMEWS.1 0.52 (0.51, 0.53) 97.9 (94.7, 99.4) 6.4 (4.8, 8.2) 19.0 (16.6, 21.6) 93.1 (83.3, 98.1)
PMEWS.2 0.53 (0.51, 0.56) 89.5 (84.3, 93.5) 17.3 (14.8, 20.0) 19.6 (17.0, 22.4) 88.0 (82.1, 92.5)
PMEWS.3 0.53 (0.51, 0.56) 89.5 (84.3, 93.5) 17.3 (14.8, 20.0) 19.6 (17.0, 22.4) 88.0 (82.1, 92.5)
PMEWS.4 0.58 (0.55, 0.61) 83.2 (77.2, 88.2) 32.5 (29.4, 35.8) 21.7 (18.8, 24.9) 89.6 (85.7, 92.8)
PMEWS.5 0.61 (0.57, 0.65) 74.9 (68.1, 80.9) 47.1 (43.7, 50.5) 24.2 (20.8, 27.8) 89.3 (86.0, 92.0)
PMEWS.7 0.64 (0.60, 0.68) 53.4 (46.1, 60.6) 74.9 (71.9, 77.8) 32.4 (27.2, 37.9) 87.7 (85.1, 90.0)
PMEWS.9 0.57 (0.53, 0.60) 23.6 (17.7, 30.2) 89.6 (87.4, 91.6) 33.8 (25.9, 42.5) 83.9 (81.3, 86.2)
PMEWS.11 0.52 (0.50, 0.54) 5.2 (2.5, 9.4) 98.8 (97.8, 99.4) 50.0 (27.2, 72.8) 82.3 (79.8, 84.6)
CATs$3 0.68 (0.64, 0.72) 48.2 (40.9, 55.5) 87.8 (85.4, 89.9) 46.9 (39.8, 54.2) 88.3 (85.9, 90.4)
CATs$4 0.60 (0.57, 0.63) 21.5 (15.9, 28.0) 98.6 (97.5, 99.3) 77.4 (63.8, 87.7) 84.8 (82.4, 87.0)
CATs$5 0.52 (0.51, 0.54) 4.2 (1.8, 8.1) 100.0 (99.6, 100.0) 100.0 (63.1, 100.0) 82.3 (79.8, 84.6)
*Combined measure of severe outcomes (Level 2/3 admission or death).
doi:10.1371/journal.pone.0034428.t003
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sensitivity/specificity pairs resulting from varying levels of the
decision threshold over the entire range of results [14]. There may
be some scenarios however, where it is very important not to miss
a ‘diagnosis’, one may opt in favour of a higher sensitivity as
compared to specificity for e.g. a disease with high mortality where
an effective treatment is available [15].
The use of lower thresholds with PMEWS (cut-off values of 1, 2,
3 or 4) demonstrated high sensitivity (77 to 98%) but it is probable
that in a pandemic situation where surge capacity is reached, these
low thresholds will not offer sufficient discrimination for healthcare
prioritisation. Positive predictive values across various thresholds
for all scoring systems were generally low but these findings may
well reflect the general mildness of 2009 pandemic influenza and
the associated low incidence of severe outcomes. As such these
measures may not predict the performance of these tools during a
more severe influenza pandemic or other highly pathogenic
pandemic. Another aspect of clinical utility is the ease of
Table 4. Predictive values of CATs, CURB-65 and PMEWS scores for predicting severe outcomes in children (,16 years, n=480).
Outcome Score ROC area (95%CI) Sensitivity % (95%CI) Specificity % (95%CI) PPV % (95%CI) NPV % (95%CI)
Level 2/3 admission CURB-65$2 0.49 (0.43, 0.55) 41.1 (29.7, 53.2) 56.8 (51.8, 61.6) 14.6 (10.0, 20.1) 84.3 (79.4, 88.4)
CURB-65$3 0.52 (0.49, 0.55) 6.8 (2.3, 15.3) 97.5 (95.5, 98.8) 33.3 (11.8, 61.6) 85.4 (81.8, 88.5)
PMEWS.1 0.51 (0.50, 0.52) 100.0 (95.1, 100.0) 2.0 (0.9, 3.8) 15.5 (12.3, 19.0) 100.0 (63.1, 100.0)
PMEWS.2 0.53 (0.52, 0.54) 100.0 (95.1, 100.0) 5.9 (3.8, 8.6) 16.0 (12.8, 19.7) 100.0 (85.8, 100.0)
PMEWS.3 0.53 (0.52, 0.54) 100.0 (95.1, 100.0) 5.9 (3.8, 8.6) 16.0 (12.8, 19.7) 100.0 (85.8, 100.0)
PMEWS.4 0.54 (0.52, 0.56) 98.6 (92.6, 100.0) 9.3 (6.7, 12.6) 16.3 (13.0, 20.1) 97.4 (86.5, 99.9)
PMEWS.5 0.55 (0.52, 0.58) 94.5 (86.6, 98.5) 15.2 (11.9, 19.1) 16.7 (13.2, 20.6) 93.9 (85.2, 98.3)
PMEWS.7 0.61 (0.56, 0.65) 86.3 (76.2, 93.2) 35.4 (30.7, 40.2) 19.3 (15.2, 24.0) 93.5 (88.4, 96.8)
PMEWS.9 0.62 (0.56, 0.68) 54.8 (42.7, 66.5) 69.0 (64.3, 73.5) 24.1 (17.8, 31.3) 89.5 (85.6, 92.7)
PMEWS.11 0.61 (0.56, 0.66) 24.7 (15.3, 36.1) 97.8 (95.8, 99.0) 66.7 (46.0, 83.5) 87.9 (84.5, 90.7)
CATs$3 0.63 (0.58, 0.69) 35.6 (24.7, 47.7) 91.2 (88.0, 93.7) 41.9 (29.5, 55.2) 88.8 (85.3, 91.6)
CATs$4 0.54 (0.51, 0.58) 9.6 (3.9, 18.8) 99.3 (97.9, 99.8) 70.0 (34.8, 93.3) 86.0 (82.5, 89.0)
CATs$5 0.51 (0.49, 0.53) 2.7 (0.3, 9.5) 99.8 (98.6, 100.0) 66.7 (9.4, 99.2) 85.1 (81.6, 88.2)
Death CURB-65$2 0.48 (0.36, 0.60) 38.9 (17.3, 64.3) 56.9 (52.3, 61.5) 3.4 (1.4, 6.9) 96.0 (92.9, 98.0)
CURB-65$3 0.51 (0.46, 0.57) 5.6 (0.1, 27.3) 97.0 (95.0, 98.3) 6.7 (0.2, 31.9) 96.3 (94.2, 97.9)
PMEWS.1 0.51 (0.50, 0.51) 100.0 (81.5, 100.0) 1.7 (0.8, 3.4) 3.8 (2.3, 6.0) 100.0 (63.1, 100.0)
PMEWS.2 0.53 (0.52, 0.54) 100.0 (81.5, 100.0) 5.2 (3.4, 7.6) 3.9 (2.4, 6.2) 100.0 (85.8, 100.0)
PMEWS.3 0.53 (0.52, 0.54) 100.0 (81.5, 100.0) 5.2 (3.4, 7.6) 3.9 (2.4, 6.2) 100.0 (85.8, 100.0)
PMEWS.4 0.54 (0.53, 0.55) 100.0 (81.5, 100.0) 8.4 (6.1, 11.4) 4.1 (2.4, 6.4) 100.0 (91.0, 100.0)
PMEWS.5 0.54 (0.49, 0.60) 94.4 (72.7, 99.9) 14.1 (11.0, 17.6) 4.1 (2.4, 6.5) 98.5 (91.8, 100.0)
PMEWS.7 0.61 (0.53, 0.69) 88.9 (65.3, 98.6) 32.9 (28.6, 37.4) 4.9 (2.8, 7.8) 98.7 (95.4, 99.8)
PMEWS.9 0.64 (0.52, 0.76) 61.1 (35.7, 82.7) 66.5 (61.9, 70.7) 6.6 (3.4, 11.5) 97.8 (95.5, 99.1)
PMEWS.11 0.62 (0.51, 0.72) 27.8 (9.7, 53.5) 95.2 (92.9, 97.0) 18.5 (6.3, 38.1) 97.1 (95.1, 98.5)
CATs$3 0.61 (0.49, 0.72) 33.3 (13.3, 59.0) 87.9 (84.5, 90.7) 9.7 (3.6, 19.9) 97.1 (95.0, 98.5)
CATs$4 0.55 (0.47, 0.62) 11.1 (1.4, 34.7) 98.3 (96.6, 99.2) 20.0 (2.5, 55.6) 96.6 (94.5, 98.0)
CATs$5 0.53 (0.47, 0.58) 5.6 (0.1, 27.3) 99.6 (98.4, 99.9) 33.3 (0.8, 90.6) 96.4 (94.4, 97.9)
Combined severe* CURB-65$2 0.49 (0.43, 0.55) 41.6 (30.4, 53.4) 56.8 (51.8, 61.7) 15.5 (10.9, 21.2) 83.6 (78.6, 87.8)
CURB-65$3 0.52 (0.49, 0.55) 6.5 (2.1, 14.5) 97.5 (95.5, 98.8) 33.3 (11.8, 61.6) 84.5 (80.9, 87.7)
PMEWS.1 0.51 (0.50, 0.52) 100.0 (95.3, 100.0) 2.0 (0.9, 3.9) 16.3 (13.1, 20.0) 100.0 (63.1, 100.0)
PMEWS.2 0.53 (0.52, 0.54) 100.0 (95.3, 100.0) 6.0 (3.9, 8.7) 16.9 (13.6, 20.6) 100.0 (85.8, 100.0)
PMEWS.3 0.53 (0.52, 0.54) 100.0 (95.3, 100.0) 6.0 (3.9, 8.7) 16.9 (13.6, 20.6) 100.0 (85.8, 100.0)
PMEWS.4 0.54 (0.52, 0.56) 98.7 (93.0, 100.0) 9.4 (6.8, 12.7) 17.2 (13.8, 21.1) 97.4 (86.5, 99.9)
PMEWS.5 0.55 (0.52, 0.58) 94.8 (87.2, 98.6) 15.4 (12.0, 19.3) 17.6 (14.1, 21.7) 93.9 (85.2, 98.3)
PMEWS.7 0.61 (0.57, 0.66) 87.0 (77.4, 93.6) 35.7 (31.0, 40.6) 20.6 (16.3, 25.4) 93.5 (88.4, 96.8)
PMEWS.9 0.63 (0.57, 0.69) 55.8 (44.1, 67.2) 69.5 (64.7, 73.9) 25.9 (19.4, 33.3) 89.2 (85.2, 92.4)
PMEWS.11 0.61 (0.56, 0.65) 23.4 (14.5, 34.4) 97.8 (95.8, 99.0) 66.7 (46.0, 83.5) 87.0 (83.5, 89.9)
CATs$3 0.65 (0.59, 0.70) 37.7 (26.9, 49.4) 91.8 (88.7, 94.3) 46.8 (34.0, 59.9) 88.5 (85.1, 91.4)
CATs$4 0.55 (0.51, 0.58) 10.4 (4.6, 19.4) 99.5 (98.2, 99.9) 80.0 (44.4, 97.5) 85.3 (81.8, 88.4)
CATs$5 0.52 (0.50, 0.54) 3.9 (0.8, 11.0) 100.0 (99.1, 100.0) 100.0 (29.2, 100.0) 84.5 (80.9, 87.6)
*Combined measure of severe outcomes (Level 2/3 admission or death).
doi:10.1371/journal.pone.0034428.t004
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measurements which are not easily or rapidly available in
community settings and the PMEWS algorithm uses a complex
weighted matrix to calculate scores [6]. CATs on the other hand,
rely on clinical indicators that can be easily and immediately
assessed in community settings and can be repeated and compared
in any setting.
The sensitivity analysis restricted to adults with proven A/
H1N1 2009 and a diagnosis of community acquired pneumonia
validated with reported radiographs shows that in the setting of
triage for this pandemic event (and only in this setting), this group
of adults would not have been disadvantaged if they were assessed
using the adult CATs.
This study shows that on the basis of AUROC values a CATs
score $3 offers the best predictive value for Level 2/3 admissions
and death when considered as independent or combined outcomes
in adults. In children, a CATs score $3 offers the best predictor of
need for higher levels of care and combined severe outcome, while
a PMEWS score .9 was marginally the better predictor of
mortality, followed closely by a CATs score $3. However, as the
95% CI for the two AUROCs overlap, a CATs score $3 would
offer a reasonable substitute given the overall better performance
across age groups for predicting higher levels of care and
combined severe outcomes.
A CATs score $3 could therefore be used to fast-track patients
of any age to critical care earlier in the hope that their survival will
improve. In a pandemic situation, when critical care is over-
burdened, clinical decision-makers may face very difficult ethical
dilemmas concerning access to critical care. CATs allow both
children and adults to be triaged within the same conceptual
framework. This will be important if scarce resources are to be
shared across wider age groups than would occur under normal
conditions. The use of CATs scores may help to ensure that
treatment access is determined in a fair way, by use of an objective
measure of likelihood of benefit from such care. The ethical
dilemmas arising in this situation have been considered elsewhere
[1].
Appropriate use of triage tools should expedite referral both to
hospital, and where scores are high, prompt consideration for
admission to Level 2/3 care. This may be associated with
improved patient outcomes. A study using the FLU-CIN cohort
found that delayed admission to hospital ($4 days after symptom
onset) was significantly associated with increased likelihood of
admission to critical care and death [16].
This study confirms the lack of effectiveness of the CURB-65
score as a triage tool for children during an influenza pandemic.
The AUROC values for CURB-65 scores in children all
approximate to 0.5, not significantly different from pure chance.
CURB-65 should not be considered for use in this, and probably
any setting involving children.
The validity of the CURB-65 score to predict mortality in adults
with A/H1N1 2009 infection both with and without radiograph
validated pneumonia is confirmed. Access to laboratory and
radiological investigations during a severe pandemic may limit the
utility of this tool.
Ideally, the clinical validity and utility of triage tools should be
studied prospectively in parallel in a community cohort of
pandemic influenza patients, to establish whether they can be
used by general practitioners to decide which patients could
benefit from hospitalisation.
Limitations
This was a case-control analysis using retrospectively collected
data derived from physicians’ first routine clinical assessment of
patients during a pandemic event. By design it is not possible to
assess intra-observer agreement, inter-observer agreement or
ability to detect change.
A potential limitation of this study relates to possible missing
data in some criteria. This applies in particular to those criteria
that depend upon clinicians recording as a matter of routine the
presence or absence of a criterion such as ‘‘capillary refill time
.2 seconds or other evidence of shock’’. As this is a secondary
data analysis based on pragmatic recording of routine clinical
assessments, the underpinning assumption is that the data
recorded on criteria is reasonably complete; however there is no
way to verify this. By default, some missing data will be incorrectly
attributed to the control group in each analysis. That is, where a
criterion is not recorded as being present, that criterion is assumed
to be absent. Attempts were made to overcome this by applying
criterion definitions to clinical data in other sections to validate
and if necessary, update variable values. Using this approach, we
were able to impute 20–35% data values, which would have
otherwise been missing data. This limitation is common to the
whole data set, reflects the reality of clinical practise, and does not
preclude fair comparison of the validity and utility of the three
tools.
A possible limitation of our study is that we used a complete-
case analysis approach. This could bias our results if the data are
not ‘missing completely at random’ (MCAR). Multiple imputation
is often recommended but it is still based on the assumption that
every subject in a randomly chosen sample can be replaced by a
new subject that is randomly chosen from the same source
population as the original subject, without compromising the
conclusions [17]. However, given that the three tools have some
common variables in their construction (particularly the ones with
missing values), one could still argue that any bias would be non-
differential and so our comparison still stands.
This study does not include comparative assessment of the
triage tools in the community. The validity and utility of triage
tools in the community remains untested.
Morbidity and mortality rates were low during this event when
compared to some previous influenza pandemics and the use of
anti-viral therapy was generally low in our cohort despite it being
widely available at the time. A more severe pandemic may be
associated with a greater acceptance of anti-viral therapy and this
may impact upon need for higher levels of care and death.
Generalisability
CATs and PMEWS were developed for use during pandemic
events and their criteria address the most likely modes of critical
illness arising from influenza, or the complications of influenza.
Both were also designed to identify sick patients most likely to
benefit from higher levels of care due to other illnesses, which at
presentation are indistinguishable from influenza like illness. CATs
may have value in other scenarios where high-bar triage is
required for both adults and children such as other severe acute
respiratory pandemic events and possibly some mass casualty
events.
Conclusions
This study shows that CATs appear better suited as a predictive
tool for severe outcomes in pandemic influenza than the CURB-
65 score and PMEWS. We propose a CATs score $3 as a decision
threshold prompting consideration for admission to higher levels
of care. This was a retrospective study and the validity and utility
of CATs needs to be assessed in a separate prospective cohort
including triage in the community. Conducting this study
prospectively in a community cohort linked to hospital outcome
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and compare the validity and utility of CATs and other triage tools
in relation to hospital admission. Since pandemics are unpredict-
able and infrequent, limited but potentially useful information
would be gained from a prospective evaluation during seasonal
influenza periods.
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